Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cancer Researcher in a Lifelong Quest (Thailand)

This article was originally published in PharmAsia News

Executive Summary

Dr. Arkom Cheirsilpa was recently honored with the Eminent Scientist 2007 Asia Award for his work in cancer prevention and treatment. Dr. Cheirsilpa is currently the deputy director for Thailand's National Cancer Institute (NCI). His award-winning efforts have focused on encouraging the wider use of inexpensive chemotherapy alternatives. Thanks to his research, Thai cancer patients have better access to a number of low-cost, cancer-fighting drugs that also offer fewer side-effects. Cheirsilpa has also done much to help the NCI better educate the country about cancer prevention and early detection. The Eminent Scientist Asia Award is presented annually by the International Research Promotion Council, a UK-based organization dedicated to furthering scientific advances in developing Asia-Pacific nations. (Click here for more

You may also be interested in...

Radical Shake-Up In Store For Entire EU Pharma Legislation

The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.

EU Pharma Strategy Will Remove Barriers And Bolster Competition

The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.

Pfizer Faces 15-Year Wait On US Adrenalin Generic

Pfizer’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts